Details
Stereochemistry | ACHIRAL |
Molecular Formula | C13H15N3O4S |
Molecular Weight | 309.341 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COCCOC1=CN=C(NS(=O)(=O)C2=CC=CC=C2)N=C1
InChI
InChIKey=QFWPJPIVLCBXFJ-UHFFFAOYSA-N
InChI=1S/C13H15N3O4S/c1-19-7-8-20-11-9-14-13(15-10-11)16-21(17,18)12-5-3-2-4-6-12/h2-6,9-10H,7-8H2,1H3,(H,14,15,16)
Molecular Formula | C13H15N3O4S |
Molecular Weight | 309.341 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Glymidine (Glycodiazine ) is a hypoglycaemic agent which has been introduced as a possible alternative to the sulphonylurea as and biguanides for the oral treatment of diabetes mellitus. It is one of a group of lipid soluble sulphapyrimidine derivatives synthesized by Gutsche et al. and bears some structural resemlance to tolbutamide. Its mode of action is similar to that of the sulphonylureas in that it appears to stimulate insulin release from the pancreas. Glycodiazine likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Membrane depolarization stimulates calcium ion influx through voltage-sensitive calcium channels. This increase in intracellular calcium ion concentration induces the secretion of insulin. It is used for the concomitant use with insulin for the treatment of noninsulin-dependent (type 2) diabetes mellitus. Glycodiazine is used concomitantly with insulin for the treatment of noninsulin-dependent (type 2) diabetes mellitus.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P48048 Gene ID: 3758.0 Gene Symbol: KCNJ1 Target Organism: Homo sapiens (Human) Sources: https://www.drugbank.ca/drugs/DB01382 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6029147
Curator's Comment: Most authors have limited the dose to 1.5g daily, but in the absence of side-effects it would seem reasonable to increase this dose when it has proved inadequate to produce good control.
The potency of glymidine is possibly slightly greater than tolbutamide, the average dose being 0.5g given twice daily, with a range of from 0.5g to 1.5g daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9017793
Glymidine exerted photohemolysis in the concentration 10(-4) mol/l
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:59:09 GMT 2025
by
admin
on
Mon Mar 31 17:59:09 GMT 2025
|
Record UNII |
4C5I4BQZ8F
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
A10BC01
Created by
admin on Mon Mar 31 17:59:09 GMT 2025 , Edited by admin on Mon Mar 31 17:59:09 GMT 2025
|
||
|
NCI_THESAURUS |
C29711
Created by
admin on Mon Mar 31 17:59:09 GMT 2025 , Edited by admin on Mon Mar 31 17:59:09 GMT 2025
|
||
|
WHO-VATC |
QA10BC01
Created by
admin on Mon Mar 31 17:59:09 GMT 2025 , Edited by admin on Mon Mar 31 17:59:09 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB01382
Created by
admin on Mon Mar 31 17:59:09 GMT 2025 , Edited by admin on Mon Mar 31 17:59:09 GMT 2025
|
PRIMARY | |||
|
102848
Created by
admin on Mon Mar 31 17:59:09 GMT 2025 , Edited by admin on Mon Mar 31 17:59:09 GMT 2025
|
PRIMARY | RxNorm | ||
|
DTXSID1023108
Created by
admin on Mon Mar 31 17:59:09 GMT 2025 , Edited by admin on Mon Mar 31 17:59:09 GMT 2025
|
PRIMARY | |||
|
SUB02387MIG
Created by
admin on Mon Mar 31 17:59:09 GMT 2025 , Edited by admin on Mon Mar 31 17:59:09 GMT 2025
|
PRIMARY | |||
|
m5813
Created by
admin on Mon Mar 31 17:59:09 GMT 2025 , Edited by admin on Mon Mar 31 17:59:09 GMT 2025
|
PRIMARY | Merck Index | ||
|
206-426-5
Created by
admin on Mon Mar 31 17:59:09 GMT 2025 , Edited by admin on Mon Mar 31 17:59:09 GMT 2025
|
PRIMARY | |||
|
Glymidine
Created by
admin on Mon Mar 31 17:59:09 GMT 2025 , Edited by admin on Mon Mar 31 17:59:09 GMT 2025
|
PRIMARY | |||
|
C72805
Created by
admin on Mon Mar 31 17:59:09 GMT 2025 , Edited by admin on Mon Mar 31 17:59:09 GMT 2025
|
PRIMARY | |||
|
C073263
Created by
admin on Mon Mar 31 17:59:09 GMT 2025 , Edited by admin on Mon Mar 31 17:59:09 GMT 2025
|
PRIMARY | |||
|
9565
Created by
admin on Mon Mar 31 17:59:09 GMT 2025 , Edited by admin on Mon Mar 31 17:59:09 GMT 2025
|
PRIMARY | |||
|
4C5I4BQZ8F
Created by
admin on Mon Mar 31 17:59:09 GMT 2025 , Edited by admin on Mon Mar 31 17:59:09 GMT 2025
|
PRIMARY | |||
|
146188
Created by
admin on Mon Mar 31 17:59:09 GMT 2025 , Edited by admin on Mon Mar 31 17:59:09 GMT 2025
|
PRIMARY | |||
|
100000086651
Created by
admin on Mon Mar 31 17:59:09 GMT 2025 , Edited by admin on Mon Mar 31 17:59:09 GMT 2025
|
PRIMARY | |||
|
1321
Created by
admin on Mon Mar 31 17:59:09 GMT 2025 , Edited by admin on Mon Mar 31 17:59:09 GMT 2025
|
PRIMARY | |||
|
339-44-6
Created by
admin on Mon Mar 31 17:59:09 GMT 2025 , Edited by admin on Mon Mar 31 17:59:09 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> INHIBITOR |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |